Company: PSTV
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047698
Chunk: 137

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 7
Chunk 137
---

     
    $
    9,939

    $
    8,544

General and administrative expenses increased by approximately $1.4 million during the year ended December 31, 2024, as compared to the same period in 2023. The increase was due primarily to an increase in legal and professional expenses of $1.0 million, and an increase of $0.4 million in compensation expenses. 

We expect general and administrative expenditures to remain generally consistent during 2025 as compared with the corresponding comparable period ended December 31, 2024. 

Share-based compensation expenses

Share-based compensation expenses include charges related to options and restricted stock awards issued to employees, directors and non-employees. We measure share-based compensation expenses based on the grant-date fair value of any awards granted to our employees. Such expense is recognized over the requisite service period.

66 

The following table summarizes the components of our share-based compensation expenses for the years ended December 31, 2024 and 2023 (in thousands):

    Years ended December 31,

    2024

    2023

    Research and development
     
    $
    51

    $
    66

    General and administrative

    499

    503

    Total share-based compensation
     
    $
    550

    $
    569

Our stock-based compensation expenses, which are impacted by grants of stock-based options, vesting schedule of such grants, as well as grant-date fair value of stock-based awards, remained consistent for the year ended December 31, 2024 and 2023.  

Other Income (Expense)

The following table summarizes interest income, interest expense, and other income and expense for the years ended December 31, 2024 and 2023 (in thousands):

    Years ended December 31,

    2024

    2023

    Interest income
     
    $
    273

    $
    400

    Interest expense

    (179
    )

    (395
    )

    Financing expense

    (3,545
    )

    —

    Change in fair value of warrants

    5,654

    —

    Warrant issuance costs

    (486
    )

    —

    Total
     
    $
    1,717

    $
    5

The decrease in interest expense for the year ended December 31, 2024 as compared to the same period in 202